Relevant bibliographies by topics / Immuno suppressive therapy

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Immuno suppressive therapy'

Author: Grafiati
Published: 2 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Immuno suppressive therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Immuno suppressive therapy"

1

Kodiyerithodi, Insaf, Shamsudeen Moideen, Benil Hafeeq, Jyothish Chalil Gopinathan, and Bhagyanath T. "Disseminated strongyloidiasis in patients on immuno-suppressive therapy." International Journal of Research in Medical Sciences 12, no. 4 (2024): 1293–96. http://dx.doi.org/10.18203/2320-6012.ijrms20240860.

Full text
Abstract:
Strongyloidiasis is a disease that causes significant morbidity and rarely mortality in immunocompromised patients. We report two cases of disseminated strongyloidiasis infection while on steroids. The first patient was a known diabetic, hypertensive, and coronary artery disease who began on steroids with hemodialysis for biopsy-proven rapidly progressive glomerulo nephritis (RPGN). He presented to the emergency department (ED) with fever, loose stools, worsening dyspnea on exertion, cough, conjunctival congestion, and bilateral lower limb pain of 1-week duration while on hemodialysis (HD). He
APA, Harvard, Vancouver, ISO, and other styles
2

Wicher, Krzysztof B., Moritz Haneklaus, Martha Lopez-Yrigoyen, et al. "Abstract LB040: MACO-355, a unique pan-LILR monoclonal antibody for cancer therapy, re-programs and stimulates immuno-suppressive macrophages in a novel ligand-binding blocking independent manner." Cancer Research 84, no. 7_Supplement (2024): LB040. http://dx.doi.org/10.1158/1538-7445.am2024-lb040.

Full text
Abstract:
Abstract Macrophages populate most solid tumors in large numbers and limit effective anti-tumoral immune responses. The leukocyte immunoglobulin-like receptors (LILR) such as e.g. LILRB1, LILRB2, and others are expressed on tumor associated macrophages. Despite sharing multiple ligands such as major histocompatibility complex class I G (HLA-G), these receptors regulate different macrophage functions such as phagocytosis or cytokine release. To date, therapeutic approaches to targeting LILRs have concentrated on blocking receptor-ligand interactions to relieve ligand-mediated immune suppression
APA, Harvard, Vancouver, ISO, and other styles
3

Tolaymat, Naser, and Clare Lenhart. "Vaccination Practice for Pediatric Inflammatory Disease Patients Receiving Immuno-suppressive Therapy." American Journal of Gastroenterology 108 (October 2013): S622—S623. http://dx.doi.org/10.14309/00000434-201310001-02051.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Dahal, Tshetiz, and Subarna Rizal. "INNATE IMMUNE CELLSIN IMMUNE TOLERANCE AFTER LIVER TRANSPLANTATION." International Journal of Advanced Research 10, no. 04 (2022): 506–15. http://dx.doi.org/10.21474/ijar01/14575.

Full text
Abstract:
Currently, liver transplantation is the most effective treatment for end-stage liver disease. Immuno-suppressive agents are required to be taken after the operations, which have significantly reduced rejection rates and improved the short-term (<1 year) survival rates. However, post-transplant complications related to the immuno-suppressive therapy have led to the development of new protocols aimed at protecting renal function and preventing de novo cancer and dysmetabolic syndrome. Donor specific immune tolerance, which means the mature immune systems of recipients will not attack the graf
APA, Harvard, Vancouver, ISO, and other styles
5

Ding, Peikun, Xiaoxiang Huang, Quanzhou Peng, et al. "Abstract 1597: Immune suppression of the lymph node microenvironment causes oligoprogression of metastatic cancer after neoadjuvant immuno-chemotherapy." Cancer Research 85, no. 8_Supplement_1 (2025): 1597. https://doi.org/10.1158/1538-7445.am2025-1597.

Full text
Abstract:
Abstract Oligometastatic disease is recognized as an intermediate state between localised and systemically metastasised disease. The diagnosis, treatment and prognosis of oligometastatic disease is currently based mainly on imaging examination. Previous clinical studies indicated that standard systemic therapy followed by radical local therapy was beneficial for survival in tumor patients with oligometastatic disease. However, different clinical outcomes (such as oligopersistant and oligoprogression) were found in synchronous and/or metachronous oligometastatic disease after the same systemic
APA, Harvard, Vancouver, ISO, and other styles
6

Singh, Alok, Priyambada Kumari, Shanker K. Singh, et al. "Pre- and post-therapy circulating immuno-stimulatory and immuno-suppressive cytokines in dogs with juvenile-onset generalized demodecosis." Veterinary Parasitology 275 (November 2019): 108954. http://dx.doi.org/10.1016/j.vetpar.2019.108954.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

DʼALESSANDRO, ANTHONY M., JOHN D. PIRSCH, ROBERT J. STRATTA, et al. "OKT3 SALVAGE THERAPY IN A QUADRUPLE IMMUNO SUPPRESSIVE PROTOCOL IN CADAVERIC RENAL TRANSPLANTATION." Transplantation 47, no. 2 (1989): 297–99. http://dx.doi.org/10.1097/00007890-198902000-00021.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Park, Seong Jin, Seho Kweon, Moyo Knowledge Mudhibadhi, Ha Rin Kim, and Youngro Byun. "Abstract 5091: Potentiating immunogenicity of PD1 blockage with metronomic Oral CAPOX for local and liver metastasized colorectal cancer." Cancer Research 83, no. 7_Supplement (2023): 5091. http://dx.doi.org/10.1158/1538-7445.am2023-5091.

Full text
Abstract:
Abstract Since the appearance of oxaliplatin, FOLFOX therapy is positioned as the standard of care for colorectal cancer (CRC). And after the advent of capecitabine, an oral prodrug of 5-FU, both FOLFOX and CAPOX remain the first-line treatment for local and advanced CRC. Even though oral 5-FU prodrug has approved more than two decades ago, orally available oxaliplatin has not been developed yet. Oral chemotherapy has garnered attention in the era of cancer immunotherapy because oral form of the therapy makes metronomic therapy feasible. In this regard, we invented orally absorbable oxaliplati
APA, Harvard, Vancouver, ISO, and other styles
9

Venkateshappa, Chandregowda, Kishore Narayanan, Rashmi Nair, et al. "Abstract 4432: A highly differentiated A2AR inhibitor for potential use in cancer therapy." Cancer Research 83, no. 7_Supplement (2023): 4432. http://dx.doi.org/10.1158/1538-7445.am2023-4432.

Full text
Abstract:
Abstract As a potent immunosuppressor adenosine is essential for maintaining tissue homeostasis and preventing an overzealous immune response during inflammation and infection. However, adenosine generated within the tumor microenvironment by the action of ectonucleotides hinders the immune reaction towards cancer cells by signaling through adenosine receptors such as high affinity A2AR expressed on immune cells. Tumors evade the immune response by usurping pathways that negatively regulate normal immune responses. Resistance to inhibition of immune checkpoint targets arises because of an upre
APA, Harvard, Vancouver, ISO, and other styles
10

Galassi, Claudia, Martina Musella, Nicoletta Manduca, Ester Maccafeo, and Antonella Sistigu. "The Immune Privilege of Cancer Stem Cells: A Key to Understanding Tumor Immune Escape and Therapy Failure." Cells 10, no. 9 (2021): 2361. http://dx.doi.org/10.3390/cells10092361.

Full text
Abstract:
Cancer stem cells (CSCs) are broadly considered immature, multipotent, tumorigenic cells within the tumor mass, endowed with the ability to self-renew and escape immune control. All these features contribute to place CSCs at the pinnacle of tumor aggressiveness and (immune) therapy resistance. The immune privileged status of CSCs is induced and preserved by various mechanisms that directly affect them (e.g., the downregulation of the major histocompatibility complex class I) and indirectly are induced in the host immune cells (e.g., activation of immune suppressive cells). Therefore, deeper in
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Immuno suppressive therapy"

1

Alamoudi, Aliaa. "Regulated antagonism of immune suppressive molecules in tumours." Thesis, University of Oxford, 2014. http://ora.ox.ac.uk/objects/uuid:95599708-58e8-4a35-92b9-4e31523556f3.

Full text
Abstract:
Despite expressing antigens that can induce immune surveillance and immune eradication, tumours demonstrate the capacity to evade anti-tumour immunity. Recently, this has been attributed to the ability of tumours to induce a local immunosuppressed micro-environment, which is a major obstacle to successful natural and vaccine induced anti-tumour immunity. Soluble factors such as transforming growth factor beta (TGFβ), and interleukin 10 (IL-10), released by cancer and stromal cells, are thought to play a significant role in this local immunosuppression. In order to assess the influence of antag
APA, Harvard, Vancouver, ISO, and other styles
2

Sandovici, Maria. "Gene therapy in kidney transplantation towards local immune suppression /." [S.l. : [Groningen : s.n.] ; University Library Groningen] [Host], 2006. http://irs.ub.rug.nl/ppn//.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

NOCI, V. M. LE. "CANCER THERAPY THROUGH TLR-INDUCED LOCAL INNATE IMMUNITY ACTIVATION AND BLOCK OF IMMUNE CHECKPOINTS OR SUPPRESSIVE CELLS." Doctoral thesis, Università degli Studi di Milano, 2017. http://hdl.handle.net/2434/480559.

Full text
Abstract:
The immunostimulatory ability of oligonucleotides containing CpG motif (CpG-ODN), agonists of TLR9, can be harnessed to promote antitumor immunity by their application at the tumor site to stimulate local activation of innate immunity; however, this is not always true for lung tumor where the immunosuppressive microenvironment, crucial to avoid tissue damage by inflammatory response to the continuous exposition to inhaled particles, limits the power of immunotherapy. Thus, the tumor microenvironment is a critical factor for successful use of these immunotherapeutics, and strategies to shift a
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Immuno suppressive therapy"

1

C, Prendergast George, and Jaffee Elizabeth M, eds. Cancer immunotherapy: Immune suppression and tumor growth. Academic Press, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

I, Gabrilovich Dmitry, and Hurwitz Arthur A, eds. Tumor-induced immune suppression: Mechanisms and therapeutic reversal. Springer, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Cancer Immunotherapy: Immune Suppression and Tumor Growth. Academic Press, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Cancer immunotherapy: Immune suppression and tumor growth. Elsevier Academic Press, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Prendergast, George C., and Elizabeth M. Jaffee. Cancer Immunotherapy: Immune Suppression and Tumor Growth. Elsevier Science & Technology Books, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

(Editor), George C. Prendergast, and Elizabeth M. Jaffee (Editor), eds. Cancer Immunotherapy: Immune Suppression and Tumor Growth. Academic Press, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Prendergast, George C., and Elizabeth M. Jaffee. Cancer Immunotherapy: Immune Suppression and Tumor Growth. Elsevier Science & Technology Books, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Suppression and regulation of immune responses: Methods and protocols. Humana Press, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Cuturi, Maria Cristina, and Ignacio Anegon. Suppression and Regulation of Immune Responses: Methods and Protocols. Humana Press, 2016.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Suppression and Regulation of Immune Responses: Methods and Protocols. Humana Press, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Immuno suppressive therapy"

1

Ural, Cihan. "Immunotherapy in Benign Hematological Diseases." In Immunotherapy in Human Cancers. Nobel Tip Kitabevleri, 2024. http://dx.doi.org/10.69860/nobel.9786053359388.5.

Full text
Abstract:
The immune system is a network of biological systems that protects an organism from diseases. Immunotherapy, also called biological therapy, treats diseases by activating or suppressing the immune system. Immunotherapy uses substances to stimulate or suppress the immune system to help the body fight cancer, autoimmune disorder and other diseases. Immunotherapeutics have transformed the treatment of malignant diseases and also afford major opportunities for treating diseases beyond cancer. Apart from cancer treatment, immunotherapy reduces an abnormal immune response in autoimmune diseases; in
APA, Harvard, Vancouver, ISO, and other styles
2

Maltsev, Dmytro. "Efficacy of rituximab in autism spectrum disorders associated with genetic deficiency of the folate cycle with signs of antineuronal autoimmunity." In IMMUNODIAGNOSTICS AND IMMUNOTHERAPY OF NEUROPSYCHIATRIC DISORDERS IN CHILDREN. TECHNOLOGY CENTER PC, 2025. https://doi.org/10.15587/978-617-8360-21-4.ch12.

Full text
Abstract:
Advances in genetics, molecular biology, and immunology over the past decades have significantly changed our understanding of the etiology and pathogenesis of autism spectrum disorders (ASD) in children. One of the key advances in this direction is the elucidation of the association of genetic deficiency of the folate cycle (GDFC) with ASD, evidence for which is based on the results of at least 5 meta-analyses of randomized controlled clinical trials and a number of additional controlled trials, the data of which have not yet been properly summarized. It has been established that GDFC leads to
APA, Harvard, Vancouver, ISO, and other styles
3

Johnson, Theodore S., and David H. Munn. "Overcoming Immune Suppression in the Tumor Microenvironment: Implications for Multi-modal Therapy." In Immunotherapy for Pediatric Malignancies. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-43486-5_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Seeling Walter, Plischke Max, and Schuh Christian. "Knowledge-Based Tacrolimus Therapy for Kidney Transplant Patients." In Studies in Health Technology and Informatics. IOS Press, 2012. https://doi.org/10.3233/978-1-61499-101-4-310.

Full text
Abstract:
Immunosuppressive therapy is necessary when patients with chronic kidney disease receive a kidney transplant. Certain immunosuppressive agents need therapeutic drug monitoring. The goal of this paper was to identify adaptation rules for Tacrolimus therapy from a clinical data set. For knowledge acquisition, patient data from 1995 to 2008 from the Department of Nephrology and Dialysis of the Vienna General Hospital were used, including patient demographics, laboratory parameters, time since kidney transplantation and other immuno-suppressive drugs administered. Tacrolimus was chosen from the av
APA, Harvard, Vancouver, ISO, and other styles
5

Roilides, Emmanuel, John Dotis, Joanna Filioti, and Elias Anaissie. "Adjunctive Antifungal Therapy." In Clinical Mycology. Oxford University PressNew York, NY, 2003. http://dx.doi.org/10.1093/oso/9780195148091.003.0010.

Full text
Abstract:
Abstract Invasive fungal infections (IFIs) have become an important problem in recent years, particularly among immuno compromised patients, such as those with cancer and those undergoing transplantation or chemotherapy. Corticosteroid treatment and phagocytic dysfunction occurring in patients with chronic granulomatous disease (CGD), human immunodeficiency virus (HIV), graft vs. host disease (GVHD) and birth prematurity are some other conditions that are associated with high frequency of IFIs. Invasive candidiasis and aspergillosis are the most frequent opportunistic IFIs. Despite recent prog
APA, Harvard, Vancouver, ISO, and other styles
6

"Human immunodeficiency virus (HIV) infection." In Oxford Handbook of Nutrition and Dietetics, edited by Joan Webster-Gandy, Angela Madden, and Michelle Holdsworth. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780199585823.003.0031.

Full text
Abstract:
Introduction, nutritional goals, and assessment 664 Unintentional weight and lean tissue loss 666 Cardiovascular risk and complications associated with HIV disease and treatment 667 Additional dietary issues 668 Untreated human immunodeficiency virus (HIV) infection leads to progressive suppression of immune function, eventually rendering the body susceptible to opportunistic infections and tumours. While there is no cure, antiretroviral therapy (ART) is highly effective in suppressing HIV replication. HIV disease is now a chronic condition and causes of death in this population have shifted f
APA, Harvard, Vancouver, ISO, and other styles
7

Berger, Joseph R., and Bruce A. Cohen. "Opportunistic infections of the nervous system in AIDS." In The Neurology of AIDS. Oxford University PressOxford, 2005. http://dx.doi.org/10.1093/oso/9780198526100.003.0045.

Full text
Abstract:
Abstract Since the first edition of this text, there have been remarkable achievements in the treatment of human immunodeficiency virus (HIV) infection. The availability of combination highly active antiretroviral therapy (HAART) has led not only to prolonged suppression of HIV replication, but also to reconstitution of the immune system. Not unexpectedly, the frequency of neurological opportunistic infections has also declined in such successfully treated individuals (Jellinger et al. 2000; Sacktor et al. 2001; Vago et al. 2002). Nonetheless, there still remains a reservoir of individuals who
APA, Harvard, Vancouver, ISO, and other styles
8

Damian, Diona L., Richard A. Scolyer, Graham Stevens, Alexander M. Menzies, and John F. Thompson. "Skin cancer: non-melanoma." In Oxford Textbook of Oncology. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199656103.003.0050.

Full text
Abstract:
Non-melanoma skin cancer (NMSC) is the most common malignancy in fair-skinned populations. In Australia, NMSC is four times as common as all other cancers combined with an incidence of ~1000 per 100 000 person-years. The vast majority of NMSC are basal cell carcinomas (BCCs), which rarely metastasize, or squamous cell carcinomas (SCCs), which do have metastatic potential, especially in immune-suppressed individuals. Because of their high frequency in the general population, and particularly in older people, NMSCs are likely to occur in many general oncology patients. Skin cancer risk can be ad
APA, Harvard, Vancouver, ISO, and other styles
9

Peine, Kevin J., Naihan Chen, Eric M. Bachelder, and Kristy M. Ainslie. "Drug Delivery Strategies for Tolerogenic Therapy for Autoimmune Diseases in an Antigen-Specific Manner." In Chronic Illness and Long-Term Care. IGI Global, 2019. http://dx.doi.org/10.4018/978-1-5225-7122-3.ch007.

Full text
Abstract:
Autoimmune diseases are the result of an improper immune response towards a self-antigen. Predominantly, autoimmune diseases have been treated using therapies that suppress systemic immune responses, which can result in significant side-effects like increased risk of infection and cancer. Alternatively, induction of immune tolerance through antigen-specific therapies can inhibit disease-associated responses without systemic suppression. Previously, immune tolerance has been accomplished by soluble antigen delivery through oral, nasal or sublingual routes. However, these therapies have shown mi
APA, Harvard, Vancouver, ISO, and other styles
10

Hall, Angela, Chris Scott, and Matthew Buckland. "Autoimmune skin disease." In Clinical Immunology. Oxford University Press, 2016. http://dx.doi.org/10.1093/hesc/9780199657650.003.0008.

Full text
Abstract:
This chapter looks at autoimmune skin diseases such as pemphigoid and pemphigus. It notes how auto-antibodies are directed against protein at the dermal-epidermal junction in the pemphigoid, while pemphigus has auto-antibodies directed against cell junctions in the epidermis. The chapter indicates that specific auto-antibodies are associated with disruption of the skin structure leading to blistering. Biopsies or serums can demonstrate the presence of auto-antibodies as well. The chapter shows how treatment can include steroid, topic, systemic, steroid-sparing systemic immune suppression, high
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Immuno suppressive therapy"

1

Liao, Wenting, Michael Overman, Adam Boutin, Scott Kopetz, Ron DePinho, and Alan Wang. "Abstract B52: KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer." In Abstracts: AACR Special Conference on Targeting RAS-Driven Cancers; December 9-12, 2018; San Diego, CA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1557-3125.ras18-b52.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Yali, Liu, Wong Chi-Chun, Liu Weixin, Ding Yanqiang, and Cheung Alivin Ho-Kwan. "IDDF2022-ABS-0088 Peptostreptococcus anaerobius drives immune suppression and immune therapy resistance in colorectal cancer." In Abstracts of the International Digestive Disease Forum (IDDF), Hong Kong, 2–4 September 2022. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2022. http://dx.doi.org/10.1136/gutjnl-2022-iddf.1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Varner, Judith A. "Abstract PL03-03: Taming the beast: Strategies to target the immune-suppressive macrophage to enhance cancer immune therapy." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-pl03-03.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Varner, Judith A. "Abstract PL03-03: Taming the beast: Strategies to target the immune-suppressive macrophage to enhance cancer immune therapy." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-pl03-03.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Cadilha, BL, MR Benmebarek, K. Dorman, et al. "10.01 Effective solid tumor therapy through enhanced recruitment and immune suppression shielded T cells." In iTOC8 – the 8th Leading International Cancer Immunotherapy Conference in Europe, 8–9 October 2021, Virtual Conference. BMJ Publishing Group Ltd, 2021. http://dx.doi.org/10.1136/jitc-2021-itoc8.1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Zhang, Yaqing, Wei Yan, Wei Yan, et al. "Abstract B23: CD4+ T lymphocytes promote pancreatic cancer progression by suppressing anti-tumor immune responses." In Abstracts: AACR Special Conference on RAS Oncogenes: From Biology to Therapy; February 24-27, 2014; Lake Buena Vista, FL. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1557-3125.rasonc14-b23.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Tomkötter, Lena, Gregor Werba, Susanna Nguy, et al. "Abstract A145: Radiation therapy induces tumor-promoting immune suppression in the microenvironment of pancreatic carcinoma." In Abstracts: CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival; September 16-19, 2015; New York, NY. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/2326-6074.cricimteatiaacr15-a145.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Krolewski, John J., Kai Sha, and Kent L. Nastiuk. "Abstract 4486: Androgen-deprivation therapy promotes immune suppression in a murine model of prostate cancer." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-4486.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Krolewski, John J., Kai Sha, and Kent L. Nastiuk. "Abstract 4486: Androgen-deprivation therapy promotes immune suppression in a murine model of prostate cancer." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-4486.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bunt, Stephanie K., Ashley M. Mohr, Jennifer M. Bailey, Paul M. Grandgenett, and Michael A. Hollingsworth. "Abstract 1554: Rosiglitazone and Gemcitabine combination therapy reduces immune suppression and modulates T cell populations in pancreatic cancer." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-1554.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Immuno suppressive therapy' for particular source types:
Journal articles Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography